UOC di Chirurgia Epato-bilio-pancreatica e Digestiva, ASST Santi Paolo e Carlo, Università di Milano, Milan, Italy.
ASST Santi Paolo e Carlo, via A. di Rudini' 8, 20142, Milan, Italy.
J Gastrointest Surg. 2018 Apr;22(4):650-660. doi: 10.1007/s11605-017-3648-y. Epub 2017 Dec 12.
When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm).
We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We performed 59 hepatic resections and 205 thermoablations through a laparoscopic approach, and they were then followed for similar follow-up (41.7 ± 31.5 months for laparoscopic hepatic resection vs. 38.7±32.3 for laparoscopic ablation therapy). Outcomes included short- and long-term morbidities, tumoral recurrence, and overall survival.
Short-term morbidity was significantly higher in the resection group (but the two groups had similar rates for severe complications) while, during follow-up, recurrence was more frequent in patients treated with thermoablation, with a clear disadvantage in terms of survival. At multivariate analysis, only the type of surgical treatment was an independent predictor of disease recurrence, while plasmatic alpha-fetoprotein and Hb values, model for end-stage liver disease score, time to recurrence, and the type of surgical treatment were independent predictors of overall survival.
Our data ultimately support some therapeutic advantages for hepatic resection in patients with a single nodule and preserved liver function. However, thermoablation is an adequate alternative in patients with nodules that would require complex surgical resections or imply a poor prognosis that might therefore better tolerate a less invasive procedure.
在符合肝储备功能的情况下,腹腔镜肝切除术仍然是治疗肝细胞癌的首选方法,而腹腔镜消融治疗则作为一种有前途的微创替代方法出现。本研究的目的是比较两组接受肝切除术或热消融治疗单个肝细胞癌(≤3cm)的同质患者。
我们从 905 例连续评估的肝细胞癌患者中纳入了 264 例肝硬化患者。我们通过腹腔镜进行了 59 例肝切除术和 205 例热消融术,然后进行了类似的随访(腹腔镜肝切除术为 41.7±31.5 个月,腹腔镜消融治疗为 38.7±32.3 个月)。结果包括短期和长期发病率、肿瘤复发和总体生存率。
切除术组的短期发病率明显较高(但两组严重并发症的发生率相似),而在随访期间,热消融治疗的患者复发更为频繁,生存明显不利。多变量分析显示,只有手术治疗类型是疾病复发的独立预测因素,而血浆甲胎蛋白和血红蛋白值、终末期肝病模型评分、复发时间和手术治疗类型是总生存率的独立预测因素。
我们的数据最终支持在肝功能正常的情况下,肝切除术对单个结节患者具有一定的治疗优势。然而,对于需要复杂手术切除或预后较差、可能更好地耐受微创治疗的患者,热消融是一种可行的替代方法。